,79 Abrogation of these mediators, their interacting receptor (CCR3/5), or downstream signaling molecules (HIF1α, circUBAP2) ameliorates tumor malignancy, and thereby representing actional targets for HCC treatment.51 Here, HIF1A is linked to hepatocellular carcinoma.